|Articles|October 15, 2001
- BioPharm International-10-01-2001
- Volume 14
- Issue 10
Inside Washington: Crisis and Costs Grip Biotech Industry
Author(s)Jill Wechsler
by Jill Wechsler Terrorist attack may postpone health policy legislation but encourage antibioterrorism initiatives.
Advertisement
Articles in this issue
almost 24 years ago
Qualification of Network Components and Validation of Networked Systemsalmost 24 years ago
Statistical Tools for Setting In-Process Acceptance Criteriaalmost 24 years ago
Managing Your Career: Recruiter-Proof Your Organizationalmost 24 years ago
Outsourcing OutlookNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5
